Active, not recruitingPhase 1NCT05078866

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

Studying Hereditary nonpolyposis colon cancer

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Eduardo Vilar-Sanchez
M.D. Anderson Cancer Center
Intervention
Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP(biological)
Enrollment
45 enrolled
Eligibility
18 years · All sexes
Timeline
20222025

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05078866 on ClinicalTrials.gov

Other trials for Hereditary nonpolyposis colon cancer

Additional recruiting or active studies for the same condition.

See all trials for Hereditary nonpolyposis colon cancer

← Back to all trials